A director at Quest Diagnostics Inc sold 1,748 shares at 175.515USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
A director at Labcorp Holdings Inc sold 6,105 shares at 248.730USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
S&P 500 and Nasdaq 100 Testing Prior 2022 Highs Since late-February (2/25/25 Compass) we expected an 8-10% pullback to provide a buying opportunity. But that all changed in last week's Compass (4/1/25), when we downgraded our outlook to bearish/cautious, citing several concerning developments (SPX and QQQ failure at 200-day MAs, bear flag breakdowns across major indexes targeting 5100-5200 on SPX, high yield spreads widening above 355bps, major tops on market leaders NVDA and META, semiconducto...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Quest Diagnostics Incorporated and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 3 April 2025 in which we reassessed the appropriateness of the ratings in th...
Moody's Ratings (Moody's) affirmed Laboratory Corporation of America Holdings' ("Labcorp") Baa2 backed senior unsecured debt rating. At the same time, we revised the outlook to stable from positive. The revision of outlook reflects our expectation of the company's continued acquisition-led busines...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Moody's Ratings (Moodys) assigned a Baa2 rating to Laboratory Corporation of America Holdings' ("Labcorp") proposed offering of backed senior unsecured notes of up to $1.8 billion. Labcorp intends to use the net proceeds from this offering, along with drawings from a new accounts receivables (A/R) s...
Moody's Ratings (Moodys) assigned a Baa1 rating to Quest Diagnostics Incorporated' ("Quest") proposed offering of senior unsecured notes. Quest intends to use the net proceeds from this offering to fund the recently announced acquisition of LifeLabs (a Canadian provider of community laboratory tests...
Moody's Ratings (Moody's) affirmed Laboratory Corporation of America Holdings' ("Labcorp") Baa2 senior unsecured debt ratings. At the same time, Moody's revised the outlook to positive from stable. The revision of outlook to positive reflects Moody's expectation that the company will continue its ...
Moody's Ratings (Moody's) upgraded the senior unsecured debt ratings of Quest Diagnostics Incorporated ("Quest") to Baa1 from Baa2. Moody's also upgraded the rating on the company's senior unsecured shelf registration to (P)Baa1 from (P) Baa2. The outlook was changed to stable from positive. ...
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the proposed offering of senior unsecured notes of Quest Diagnostics Incorporated ("Quest"). There are no changes to Moody's existing ratings of Quest including the Baa2 senior unsecured long-term ratings. The outlook remains unchanged ...
Moody's Investors Service ("Moody's") affirmed the senior unsecured ratings of Quest Diagnostics Incorporated ("Quest") at Baa2. At the same time, Moody's revised the outlook to positive from stable. The revision in outlook to positive reflects Moody's expectation for solid operating performance w...
BURLINGTON, N.C.--(BUSINESS WIRE)-- Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the third quarter ended Sept. 30, 2022, and updated full-year guidance. "Labcorp made important strategic progress this quarter and is well positioned to deliver sustained value and growth,” said Adam Schechter, chairman and CEO of Labcorp. “We are focusing on science, innovation and technology to serve our customers' needs. Our Diagnostics Base Business performed well, and our Drug Development Base Business fundamentals remain strong, despite challenging year-over-year ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.